These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6318205)

  • 1. CCK-8 modulation of mesolimbic dopamine: antagonism of amphetamine-stimulated behaviors.
    Schneider LH; Alpert JE; Iversen SD
    Peptides; 1983; 4(5):749-53. PubMed ID: 6318205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
    Crawley JN
    J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.
    Vaccarino FJ; Rankin J
    Behav Neurosci; 1989 Aug; 103(4):831-6. PubMed ID: 2765186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of cholecystokinin on central monoaminergic pathways.
    Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR
    Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G; Itoh S; Hsiao S
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infusions of cholecystokinin octapeptide into the ventral tegmental area potentiate amphetamine conditioned place preferences.
    Pettit HO; Mueller K
    Psychopharmacology (Berl); 1989; 99(3):423-6. PubMed ID: 2594910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents.
    Van Ree JM; Gaffori O; De Wied D
    Eur J Pharmacol; 1983 Sep; 93(1-2):63-78. PubMed ID: 6138272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer.
    Phillips GD; Robbins TW; Everitt BJ
    Psychopharmacology (Berl); 1994 Mar; 114(2):345-59. PubMed ID: 7838928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of radio-frequency lesions of the nucleus accumbens on d-amphetamine-induced locomotor and rearing behavior in rats.
    Kehne JH; Sant WW; Sorenson CA
    Psychopharmacology (Berl); 1981; 75(4):363-7. PubMed ID: 6803281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of ventral pallidal neurons to amygdala stimulation and its modulation by dopamine projections to nucleus accumbens.
    Yim CY; Mogenson GJ
    J Neurophysiol; 1983 Jul; 50(1):148-61. PubMed ID: 6875644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the rat mesolimbic dopamine pathway by neurokinins.
    Elliott PJ; Mason GS; Graham EA; Turpin MP; Hagan RM
    Behav Brain Res; 1992 Oct; 51(1):77-82. PubMed ID: 1282818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems.
    Koob GF; Simon H; Herman JP; Le Moal M
    Brain Res; 1984 Jun; 303(2):319-29. PubMed ID: 6430466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
    Weiss F; Ettenberg A; Koob GF
    Psychopharmacology (Berl); 1989; 99(3):409-15. PubMed ID: 2574480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin modulation of locomotor behavior in rats is sensitized by chronic amphetamine and chronic restraint stress exposure.
    Wunderlich GR; Rotzinger S; Bush DE; DeSousa NJ; Vaccarino FJ
    Brain Res; 2004 Mar; 1001(1-2):95-107. PubMed ID: 14972658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balance of glutamate and dopamine in the nucleus accumbens modulates self-stimulation behavior after injection of cholecystokinin and neurotensin in the rat brain.
    Heidbreder C; Gewiss M; De Mot B; Mertens I; De Witte P
    Peptides; 1992; 13(3):441-9. PubMed ID: 1523160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine and conditioned reinforcement. II. Contrasting effects of amphetamine microinjection into the nucleus accumbens with peptide microinjection into the ventral tegmental area.
    Kelley AE; Delfs JM
    Psychopharmacology (Berl); 1991; 103(2):197-203. PubMed ID: 1709289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.
    Costall B; Domeney AM; Naylor RJ; Tyers MB
    Br J Pharmacol; 1987 Dec; 92(4):881-94. PubMed ID: 2962686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion.
    Crawley JN
    Synapse; 1989; 3(4):346-55. PubMed ID: 2740993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.